Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Share-based Compensation (2016 - 2025)

Altimmune (ALT) has disclosed Share-based Compensation for 16 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 15.46% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.5 million, a 7.26% increase, with the full-year FY2024 number at $14.4 million, up 35.27% from a year prior.
  • Share-based Compensation was $3.6 million for Q3 2025 at Altimmune, roughly flat from $3.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.3 million in Q2 2024 to a low of $1.2 million in Q1 2021.
  • A 5-year average of $2.6 million and a median of $2.7 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 466.72% in 2021, then decreased 17.28% in 2025.
  • Altimmune's Share-based Compensation stood at $1.3 million in 2021, then surged by 43.44% to $1.9 million in 2022, then soared by 30.5% to $2.5 million in 2023, then soared by 35.84% to $3.4 million in 2024, then increased by 5.96% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Share-based Compensation are $3.6 million (Q3 2025), $3.6 million (Q2 2025), and $4.0 million (Q1 2025).